Technology Intelligence
Cancer Genomics
MedTwenty Technology Score 88Diagnostics
Comprehensive genomic profiling, minimal residual disease testing and tumour-informed sequencing.
Market size$12.4bn (2026)
Growth18% CAGR to 2030
Funding (12m)$2.4bn raised in the last twelve months
Quarterly change+28% q/q
Timeline
- Sep 2026Tempus agrees $1.5bn acquisition of Personalis.
Segment forecasts and vendor benchmarks
Professional membership unlocks five-year segment forecasts, contracted-volume benchmarks and comparison across the full technology universe.
Upgrade